Skip to main content
Have a personal or library account? Click to login
The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors Cover

The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

Radiology and Oncology
Volume 55 (2021): Issue 2 (June 2021)
By: ,  ,  ,   and    
Open Access
|Dec 2020
Figures & tables

Figures & Tables

Figure 1

ROC curve for predicting cystoscopic finding.

Figure 2

ROC curve for histology prediction.

Table 1

Summary of the patients’ demographics and test results numbers

GenderNumber of patientsMean age, years ± SD
All54 (100.0%)70.5 ± 8.8
Male42 (77.8%)70.5 ± 8.7
Female12 (22.2%)70.5 ± 9.6
Noninvasive test / standard invasive diagnostic procedureNumber of patients with TP / FN / TN / FP noninvasive test result
XBC / cystocopy (LDATC 0.4923)9 / 3 / 40 / 2
XBC / cystocopy (LDATC 0.5)8 / 4 / 40 / 2
VUC / cystoscopy5 / 7 / 41 / 1
XBC / histology (LDATC 0.4923)10 / 3 / 40 / 1
XBC / histology (LDATC 0.5)9 / 4 / 40 / 1
VUC / histology5 / 8 / 40 / 1

[i] FN = false negative; FP = false positive; LDATC = linear discriminant analysis total cut-off; SD = standard deviation; TN = true negative; TP = true positive; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

Table 2

Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive cystoscopic findings

TestSensitivitySpecificityPPVNPV
XBC, LDATC 0.492375.0%95.2%81,8%93.0%
XBC, LDATC 0.566.7%95.2%80.0%90.9%
VUC41.7%97.6%83.3%85.4%
XBC, LDATC 0.4923 + VUC75.0%95.2%81,8%93.0%

[i] LDATC = linear discriminant analysis total cut-off; NPV = negative predictive value; PPV = positive predictive value; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

Table 3

Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive histological results

TestSensitivitySpecificityPPVNPV
XBC, LDATC 0.492376.9%97.5%90,9%93.0%
XBC, LDATC 0.569.2%97.5%90.0%90.9%
VUC38.4%97.5%83.3%83.3%
XBC, LDATC 0.4923 + VUC76.9%97.5%90,9%93.0%

[i] LDATC = linear discriminant analysis total cut-off; NPV = negative predictive value; PPV = positive predictive value; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

Table 4

Sensitivity of the XBC and voided urinary cytology stratified by tumour stage and grade. Number of cases detected by noninvasive test against number of cases detected by hystology analysis is shown in the parenthsis

Test / StageCISTaT1T2GradePUNLMPlow gradehigh grade
XBC, LDATC 0.4923100%
(2/2)		80.0%
(4/5)		100%
(2/2)		100%
(1/1)		0.0%
(0/1)		66.7%
(2/3)		100.0%
(7/7)
VUC50.0%
(1/2)		40.0%
(2/5)		50.0%
(1/2)		100%
(1/1)		0.0%
(0/1)		66.7%
(2/3)		42.9%
(3/7)

[i] LDATC = linear discriminant analysis total cut-off; PUNLMP = papillary urinary neoplasm of low malignant potential; VUC = voided urinary cytology; XBC = Xpert BC Monitor Test

DOI: https://doi.org/10.2478/raon-2020-0072 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099
Journal RSS Feed
Language: English
Page range: 196 - 202
Submitted on: Sep 22, 2020
Accepted on: Nov 3, 2020
Published on: Dec 29, 2020
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
cystoscopy,
Xpert BC Monitor Test,
urinary bladder neoplasm,
voided urinary cytology
Related subjects:
Medicine,
Clinical medicine,
Radiology

© 2020 Tomaz Smrkolj, Urska Cegovnik Primozic, Teja Fabjan, Sasa Sterpin, Josko Osredkar, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 55 (2021): Issue 2 (June 2021)
Previous article
Next article